News & Trends - Pharmaceuticals

Lilly’s therapy hits significant goal in early breast cancer

Health Industry Hub | June 29, 2020 |
[Total: 1    Average: 5/5]

Pharma News: Eli Lilly’s Verzenio has become the first CDK4/6 inhibitor to show it can significantly cut the risk of cancer recurrence for people with high-risk HR-positive, HER2-negative early breast cancer.

Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the primary endpoint of invasive disease-free survival (IDFS), significantly decreasing the risk of breast cancer recurrence or death compared to standard adjuvant ET alone.

These results are from a pre-planned interim analysis of the Phase III monarchE study – making Verzenio the only CDK4 & 6 inhibitor to demonstrate a statistically significant reduction in the risk of cancer recurrence for people with high risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer.

“When a person is diagnosed with high risk early stage breast cancer, they strive to do everything in their power to prevent a recurrence. And as clinicians, we have the same goal,” said Maura Dickler, M.D., vice president of oncology, late-phase development, Lilly Oncology. “monarchE was intentionally designed for people whose breast cancer is at a high risk of returning. We are incredibly excited by the results of monarchE and that we can potentially offer a new treatment option for patients with high risk HR+, HER2- early breast cancer. This would not have been possible without the tremendous commitment from the people who participated in this trial.”

Lilly’s win puts pressure on its in-class competitors, Pfizer’s Ibrance (palbociclib) and Novartis’ Kisqali (ribociclib). 

Despite progress in the treatment of breast cancer, approximately 30% of people diagnosed with HR+, HER2- early breast cancer are at risk of their cancer returning. This risk of recurrence increases based on certain clinical and/or pathological features such as breast cancer that has spread to the lymph nodes, a larger tumour size and a higher tumour grade. New treatment options are needed to advance the field and help prevent early breast cancer from returning, potentially to an incurable metastatic stage.

Anne White, President, Lilly Oncology, said “Verzenio in combination with endocrine therapy has demonstrated positive results in people with high risk HR+, HER2- early breast cancer – a major milestone with the potential to change the paradigm of how early breast cancer is treated and a first for the CDK4 & 6 inhibitor class. The fact that these results were achieved early, at the interim analysis, is also exciting because it will help us speed this innovation to people who need it. We look forward to submitting these data to regulatory authorities before the end of 2020.” 

Selfcare In Healthcare Coalition on Mental Health Support in Pharma, Biotech and MedTech

In Australia, Verzenio is currently reimbursed and indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or following prior endocrine therapy.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Medical

Medical Pharma Biotech MedTech - Medical researchers support interim budget measures and urge longer-term sustainability - Research Australia

Medical researchers support interim budget measures and urge longer-term sustainability

Health Industry Hub | September 28, 2020 |

Medical News: The $700 million bail-out package for university researchers flagged for consideration in the upcoming federal budget would be […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Pfizer Australia backs digital health start-ups, an interview with Country Medical Director Dr Krishan Thiru

Pfizer Australia backs digital health start-ups, an interview with Country Medical Director

Health Industry Hub | September 28, 2020 |

Digital & Innovation: The recent Innovate Health virtual event aimed at navigating commercialisation, accelerating growth and uptake of digital health […]

More


News & Trends - Medical Technology

MedTech News - Documentation of COVID-19 screening fell short of national imperative in Australian hospitals

Documentation of COVID-19 screening fell short of national imperative in Australian hospitals, says new study

Health Industry Hub | September 28, 2020 |

MedTech News: New Australian research on COVID-19 screening of hospital patients during the first wave of the pandemic found that […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche's haemophilia treatment available at no cost to patients

Roche’s haemophilia treatment available at no cost to patients

Health Industry Hub | September 28, 2020 |

Pharma News: The Australian government have agreed to fund a new treatment for haemophilia patients, through the national blood arrangements. […]

More